101832-10-4

Basic information

• Product Name: 2,2,2-trifluoro-1-(5-nitro-1H-indol-3-yl)ethanone
• CAS NO: 101832-10-4
• Molecular Formula: C₁₀H₅F₃N₂O₃
• Molecular Weight: 258.1535
• Mol File: 101832-10-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 400.4°C at 760 mmHg
• Flash Point: 195.9°C
• Density: 1.597g/cm³
• Vapor Pressure: 1.28E-06mmHg at 25°C
• Refractive Index: 1.603
• CAS DataBase Reference: 2,2,2-trifluoro-1-(5-nitro-1H-indol-3-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2,2-trifluoro-1-(5-nitro-1H-indol-3-yl)ethanone(101832-10-4)
• EPA Substance Registry System: 2,2,2-trifluoro-1-(5-nitro-1H-indol-3-yl)ethanone(101832-10-4)

Safety Data

• Hazardous Substances Data: 101832-10-4(Hazardous Substances Data)

Usage

General Description

2,2,2-trifluoro-1-(5-nitro-1H-indol-3-yl)ethanone, also known as TRIMEB, is a synthetic compound with the molecular formula C10H6F3NO3. It is a white to off-white solid that is used as a reagent in organic synthesis and pharmaceutical research. TRIMEB contains a trifluoromethyl group and a nitrophenyl group, giving it useful properties for chemical reactions and biological studies. The compound is often used as a building block in the synthesis of complex organic molecules and has potential applications in drug discovery and development. Due to its unique structure and reactivity, TRIMEB has attracted attention from researchers in various fields of chemistry and molecular biology.

Upstream product

• 6146-52-7 5-nitroindole 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 128200-32-8 5-nitro-1H-indole-3-carboxamide 
• 6958-37-8 5-nitro-1H-indole-3-carboxylic acid 

Relevant articles and documents

Synthesis and antioxidant activity of new tetrahydro-naphthalene-indole derivatives as retinoid and melatonin analogs

A number of retinoid-related compounds represent classes of antioxidative and proapoptotic agents with promising potential in the treatment of neoplastic diseases. Indeed, the synthetic retinoid amide fenretinide [N-(4-hydroxyphenyl) retinamide] induces apoptosis of cancer cells and acts as a chemotherapeutic drug in cancer therapy. In the present work, and as a continuation of our studies on retinoid-type compounds, the synthesis of melatonin retinamide derivatives was studied as a novel series of melatonin retinoids, using the condensation reaction sequence involving tetrahydrotetramethylnaphthalene carboxylic acid and appropriate melatonin-type moieties. Despite of the weak DPPH inhibition activity pattern of the synthesized compounds, some of them showed a strong inhibition on lipid peroxidation (IVa-b, Va, and VIIa-c, 88, 96, 90, 94, 93, and 86%, respectively at 10-4 M concentration) when melatonin (85% at 10-4 M concentration) was used as a reference compound.

AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS

The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1 ), and their use as pharmaceutical compositions.